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This study aimed to assess the prognostic value of 18F-FDG uptake in
hepatocellular carcinoma (HCC) patients who had transarterial che-
moembolization (TACE) or concurrent intraarterial chemotherapy with
external-beam radiotherapy (CCRT) and to compare the prognosis
between patients treated with TACE and those with CCRT according
to 18F-FDG uptake. Methods: Two hundred fourteen intermediate–
to–advanced-stage HCC patients without extrahepatic metastasis
who underwent staging 18F-FDG PET/CT before TACE (153 patients)
or CCRT (61 patients) were recruited from 7 hospitals. Progression-
free survival (PFS) and overall survival (OS) were compared using an
optimal cutoff value for tumor-to-normal liver uptake ratio (TLR). Fur-
ther, PFS and OS were compared according to treatment modalities
(TACE vs. CCRT) using the same TLR cutoff value. Results: On
multivariate analysis, age and TLR were independent prognostic
factors for PFS (P , 0.050). For OS, Child–Pugh classification and
TLR were independent prognostic factors (P , 0.050). When the
TLR was greater than 2.0, patients treated with CCRT showed sig-
nificantly better PFS and OS than those treated with TACE after
adjusting for tumor size and number (P 5 0.014, for all). In contrast,
there was no significant difference in PFS and OS between pa-
tients treated with TACE or CCRT when the TLR was 2.0 or less.
Conclusion: 18F-FDG uptake was an independent prognostic factor
for PFS and OS in HCC patients treated with TACE or CCRT.
Especially, in HCCs with high 18F-FDG uptake, patients treated
with CCRT showed better survival than those treated with TACE.
18F-FDG PET/CT may help determine the treatment modality for
intermediate–to–advanced-stage HCCs.
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For patients with hepatocellular carcinoma (HCC), the Barce-
lona Clinic Liver Cancer (BCLC) staging system has been used to
select the optimal treatment and predict the prognosis (1). In pa-
tients with very early–to–early stage HCC, curative surgical resec-
tion can be performed, and a 5-y survival rate of more than 60% has
been reported (2). With only about 30% of patients able to undergo
curative treatments, most HCC patients are referred for noncurative
treatments (1,3). For intermediate–to–advanced-stage HCC patients
without extrahepatic metastasis, transarterial chemoembolization
(TACE) is the first-line treatment (1,4,5); however, diverse treat-
ment modalities have been used to improve the treatment response
and prognosis (6,7). Local radiotherapy has been effective in con-
trolling HCC progression (8), and concurrent intraarterial chemo-
therapy with external-beam radiotherapy (CCRT) has recently been
considered as an attractive alternative treatment strategy for locally
advanced HCC (9–11).
18F-FDG PET/CT has been effective for staging and detecting
extrahepatic metastasis and recurrence in HCC patients, although
18F-FDG PET/CT shows low sensitivity for detecting intrahepatic
HCCs (12–14). More importantly, as the degree of 18F-FDG uptake
is associated with tumor differentiation and aggressiveness (15,16),
treatment response and prognosis appear to differ between HCCs
with high and low 18F-FDG uptake (17,18). However, no study has
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evaluated the potential of 18F-FDG uptake in deciding treatment
modalities with better prognosis in HCC patients.
The purpose of this retrospective multicenter cohort study was to
assess the prognostic value of 18F-FDG uptake in intermediate–to–
advanced-stage HCC patients without extrahepatic metastasis and to
compare prognosis between patients treated with TACE and those treated
with CCRT as an initial treatment according to 18F-FDG uptake.
MATERIALS AND METHODS
Patients
This retrospective, multicenter cohort study was approved by the
institutional review boards of 7 participating university hospitals
(Dongsan Medical Center, Incheon St. Mary’s Hospital, Kyung Hee
University Hospital, Samsung Medical Center, Seoul St. Mary’s Hos-
pital, Uijeongbu St. Mary’s Hospital, and Yonsei University Health
System), and the requirement to obtain informed consent was waived.
We retrospectively reviewed the medical records of 847 patients with
HCC who underwent staging 18F-FDG PET/CT before treatment be-
tween January 2009 and December 2010 at the 7 participating institu-
tions (Supplemental Table 1; supplemental materials are available at
http://jnm.snmjournals.org). Of these patients, 214 patients were enrolled
in the study according to the following inclusion criteria (Fig. 1): patients
with HCC diagnosis by histopathology or noninvasive diagnostic criteria of
the American Association for the Study of Liver Disease guidelines (3), no
treatment before 18F-FDG PET/CT, BCLC stage B or C, no extra-
hepatic metastasis on staging work-up studies, and patients who un-
derwent TACE or CCRT as an initial treatment. Routine staging
work-up including physical examination, blood tests, contrast-enhanced
liver CT, 18F-FDG PET/CT, and liver MRI (if needed) were completed
before initial treatment. All the clinical data of enrolled patients were
collected and managed with an Internet-based Clinical Research and
Trial Management System of the Korea National Institute of Health.
18F-FDG PET/CT
18F-FDG PET/CTwas performed with a dedicated PET/CT scanner
(Discovery Ste [GE Healthcare] for Dongsan Medical Center, Incheon
St. Mary’s Hospital, Samsung Medical Center, and Yonsei University
Health System; Gemini TF16 [Philips Healthcare] for Kyung Hee Uni-
versity Hospital; Biograph TruePoint [Siemens Healthcare] for Seoul St.
Mary’s Hospital, Uijeongbu St. Mary’s Hospital, and Yonsei University
Health System; and Biography Duo [Siemens Healthcare] for Seoul St.
Mary’s Hospital). All patients fasted for at least 6 h before intravenous
administration of 18F-FDG, and the blood glucose levels of enrolled
patients, which were measured before the injection of 18F-FDG, were
140 mg/dL or less. A dose of 5.5 MBq/kg of 18F-FDG was intravenously
administered for Discovery STe and 6.0 MBq/kg for Biograph TruePoint
and Biograph Duo, and 333 MBq of 18F-FDG were administered for
Gemini TF16. In all institutions, 60 min after injection of 18F-FDG, a
PET/CT scan was acquired from the cerebellum to the proximal thighs.
First, a CT scan was obtained without contrast enhancement. Immedi-
ately after CT acquisition, a PET scan was obtained in 3-dimensional
mode. PET images were reconstructed with an iterative reconstruction
algorithm using CT images for attenuation correction.
TACE and CCRT
In patients without portal vein tumor thrombosis, TACE was consid-
ered to be the standard treatment; however, in patients with large
tumors of 10.0 cm or more, CCRT was recommended. In patients
with portal vein tumor thrombosis, TACE or CCRT was recom-
mended according to the clinical conditions of the patients. The
median interval between 18F-FDG PET/CT and the initial treatment
was 3.0 d (range, 1.0–45.0 d). For patients treated with TACE, celiac
and superior mesenteric angiography was initially performed to evaluate
tumor-feeding arteries and portal vein tumor thrombosis. Afterward, the
feeding artery was selectively catheterized and the chemotherapeutic
agents were administered as an oil emulsion, followed by the embolic
materials. In patients with residual viable HCC on follow-up imaging
studies, repeated TACE was performed. For patients treated with CCRT,
3-dimensional conformal radiotherapy was initially performed at a
total dose of 45 Gy in 25 fractions of 1.8 Gy over 5 wk. Concurrent
continuous-infusion hepatic arterial 5-fluorouracil was delivered dur-
ing the first and fifth weeks of radiotherapy through a percutaneous
hepatic arterial catheter. One month after CCRT, 5-fluorouracil and
cisplatin were administered every 4 wk for 3–12 cycles according
to treatment response. After initial treatment, all patients were closely
monitored based on physical examinations, serum a-fetoprotein (AFP)
level, and liver CT. The median duration of clinical follow-up was
10.7 mo (range, 0.3–67.4 mo).
Image Analysis
The 18F-FDG PET/CT, contrast-enhanced liver CT, and liver MR
images of 847 HCC patients were transferred using the Digital Imag-
ing and Communications in Medicine protocol and stored on a
server at the designated center (National Cancer Center, Goyang-
si Gyeonggi-do, Korea). The PET/CT images of 214 patients enrolled
in the study were retrospectively reviewed by 2 board-certified nuclear
medicine physicians. Discrepancies between the interpreters were
resolved by a consensus reading. First, the PET/CT and contrast-
enhanced CT images of all patients were visually assessed and regis-
tered using a fusion module provided by the commercially available
imaging software (MIM-6.4; MIM Software Inc.). Afterward, a spheric-
shaped volume of interest was drawn for each HCC on contrast-
enhanced CT images, and the SUVmax was calculated as follows:
(decay-corrected activity [kBq]/tissue volume [mL])/(injected 18F-FDG
activity [kBq]/body mass [g]). In patients with multiple HCC lesions,
the tumor showing the highest SUVmax was measured. For the mea-
surement of 18F-FDG uptake in the normal liver, 3 spheric-shaped,
1-cm-sized volumes of interest were drawn in the liver, 2 in the right
lobe, and 1 in the left lobe, at a location for which the HCC was notFIGURE 1. Flowchart of patient selection.
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detected on contrast-enhanced CT or MRI. The SUVmean of the 3 vol-
umes of interest was calculated and defined as the SUVmean of the
normal liver. The uptake ratio of SUVmax of HCC to mean SUVmean
of the normal liver (tumor–to–normal liver uptake ratio [TLR]) was
calculated for each patient.
Statistical Analysis
Characteristics of patient groups treated with TACE or CCRT were
compared using the Student t test and the x2 test. Kaplan–Meier survival
analysis was performed to calculate the cumulative progression-free sur-
vival (PFS) and overall survival (OS). Survival time was defined as the
time from initial treatment to the date of the detection of disease progres-
sion (for PFS) or death (for OS) or to the date of the last follow-up visit.
Disease progression was defined as progressive disease ($20% increase in
the size of known HCC lesions from baseline or occurrence of newly
developed metastases on follow-up imaging studies) according to
RECIST, version 1.1. The prognostic values of the variables were assessed
using a log-rank test in univariate analysis and a Cox proportional hazards
regression test in multivariate analysis. All continuous variables were di-
chotomized according to specific cutoff values. The optimal cutoff values
were determined using receiver-operating-characteristic curve analysis.
Cumulative PFS and OS stratified by the TLR cutoff value were
compared between the patients treated with TACE and those with
CCRT using Kaplan–Meier survival analysis with a log-rank test.
Statistical analyses were performed using SPSS (version 20.0 for




The characteristics of enrolled patients are shown in Table 1. Of
214 patients, 108 patients (50.5%) had portal vein tumor thrombus
and were classified as BCLC stage C, whereas the remaining 106
patients (49.5%) were stage B. As an initial treatment, 153 patients
(71.5%) underwent TACE and the remaining 61 patients (28.5%)
underwent CCRT. The patient group treated with CCRT (Fig. 2) had
a significantly larger tumor size, higher TLR, and higher proportion
of portal vein tumor thrombosis (P, 0.050); meanwhile, the patient
group with TACE (Fig. 3) showed a higher proportion of multiple
tumors (P , 0.001). During follow-up, 152 patients (71.0%) expe-
rienced disease progression, and 172 patients (80.4%) died. The
median PFS and OS were 7.5 and 12.4 mo, respectively.
Prognostic Significance of 18F-FDG PET and Clinical Factors
Age, sex, etiology, Child–Pugh classification, treatment modality,
tumor size and number, portal vein tumor thrombosis, serum AFP
level, and TLR were evaluated as variables in survival analysis. The
cutoff values, determined by receiver-operating-characteristic curve
analyses, for age, tumor size, serum AFP level, and TLR were 60 y,
6.0 cm, 500.0 ng/dL, and 2.0, respectively. The prognostic signifi-
cance of the variables for PFS and OS is shown in Tables 2 and 3.
On univariate analysis, age, tumor size, portal vein tumor thrombo-
sis, and TLR (Fig. 4A) were significant prognostic factors for PFS
TABLE 1
Patient Characteristics
Characteristic Total (n 5 214) TACE (n 5 153) CCRT (n 5 61) P
Age (y)* 58 (27–88) 59 (27–88) 60 (39–80) 0.400
Sex 0.738
Men 180 (84.1%) 130 (85.0%) 50 (82.0%)
Women 34 (15.9%) 23 (15.0%) 11 (18.0%)
Diabetes mellitus 58 (27.1%) 39 (25.5%) 19 (31.1%) 0.503
Etiology 0.388
HBV 152 (71.0%) 110 (71.9%) 42 (68.9%)
HCV 17 (7.9%) 12 (7.8%) 5 (8.2%)
Alcohol 19 (8.9%) 16 (10.5%) 3 (4.9%)
Other 26 (12.1%) 15 (9.8%) 11 (18.0%)
Child–Pugh classification 0.266
A 182 (85.0%) 127 (83.0%) 55 (90.2%)
B 32 (15.0%) 26 (17.0%) 6 (9.8%)
Tumor size (cm)* 8.0 (1.3–20.0) 6.3 (1.3–17.6) 10.0 (2.5–20.0) ,0.001
Tumor number ,0.001
Single 76 (35.5%) 39 (25.5%) 37 (60.7%)
Multiple 138 (64.5%) 114 (74.5%) 24 (39.3%)
Portal vein tumor thrombosis 0.003
Absence 106 (49.5%) 86 (56.2%) 20 (32.8%)
Presence 108 (50.5%) 67 (43.8%) 41 (67.2%)
Serum AFP (ng/dL)* 427.3 (1.6–435,220.0) 325.7 (2.7–435,220.0) 1,059.0 (1.6–120,000.0) 0.853
TLR* 2.6 (1.1–11.6) 2.2 (1.1–9.8) 3.3 (1.3–11.6) 0.007
*Data are median value, with range in parentheses.
HBV 5 hepatitis B virus; HCV 5 hepatitis C virus.
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(P , 0.050). For OS, Child–Pugh classification, serum AFP level,
tumor size, portal vein tumor thrombosis, and TLR (Fig. 4B) were
significant prognostic factors (P , 0.050).
On multivariate analyses using significant variables in the univar-
iate analyses, age and TLR were independent prognostic factors for
PFS (Table 2; P , 0.050), and Child–Pugh classification and TLR
were determined to be significant prognostic factors for OS (Table 3;
P , 0.050).
Comparison of Prognosis Between TACE and CCRT
Stratified by 18F-FDG Uptake
There was no significant difference in PFS (Fig. 5A) and OS
(Fig. 5B) between TACE and CCRT in all patients (P 5 0.054 for
PFS and P 5 0.280 for OS). PFS and OS between patients treated
with TACE and those with CCRTwere compared according to the
TLR cutoff value (Table 4). In the patient group with a TLR
greater than 2.0, the patients treated with CCRT showed a signif-
icantly better PFS (P 5 0.018, Fig. 6A) and OS (P 5 0.009, Fig.
6B) than the patients treated with TACE. The median OS for
patients treated with CCRT was 11.4 mo, whereas the median
OS for patients treated with TACE was only 7.9 mo. Because both
tumor size and number can potentially act as confounding factors,
we further evaluated an association between treatment modality
and prognosis after adjusting for tumor size and number. Even
after adjusting for tumor size and number, the patients treated with
CCRT still showed a lower progression risk (P 5 0.014; hazard
ratio, 0.61; 95% confidence interval, 0.41–0.90) and a lower mortality
risk (P 5 0.014; hazard ratio, 0.58; 95% confidence interval, 0.37–
0.89) than those treated with TACE. In contrast, there were no signif-
icant differences in PFS (P 5 0.187) and OS (P 5 0.927) between
patients treated with TACE and those with CCRT in the patient group
with a TLR of 2.0 or less.
DISCUSSION
In the present multicenter retrospective study, the prognostic value
of 18F-FDG uptake for each tumor was assessed in intermediate–
to–advanced-stage HCC patients who underwent TACE or
CCRT. Currently, the value of 18F-FDG uptake as an independent
prognostic factor is controversial in this group of patients (18–22);
however, in this study, we found that the TLR of HCC was a significant
independent prognostic factor for both PFS and OS. The patients
with a TLR of 2.0 or less had a median PFS of 9.8 mo and a
median OS of 24 mo, whereas a median PFS of 6.2 mo and a median
OS of less than 10 mo were found in patients with a TLR greater
than 2.0. Furthermore, in patients with a TLR greater than 2.0,
patients treated with CCRT showed significantly lower disease
progression and mortality risk than those treated with TACE.
It is important to know whether 18F-FDG uptake on PET/CT at
the time of staging is associated with clinical outcomes. However,
the more clinically relevant question might be whether the finding
would be helpful in selecting treatments with subsequent changes in
patient prognosis. In this regard, we assessed the difference in clin-
ical outcomes between TACE and CCRT according to the 18F-FDG
uptake of HCC. In the patient group with a TLR greater than 2.0,
patients treated with TACE showed a significantly worse PFS and
OS than patients treated with CCRT even after adjusting for tumor
size and number. TACE is considered as the treatment of choice for
intermediate-to-advanced HCC without extrahepatic metastases
(1,4,5). However, it could be that it is insufficient for achieving a
complete response in large advanced HCCs (23). In fact, hepatic
artery perfusion, which is related to successful TACE, is negatively
correlated with 18F-FDG uptake of HCC and has been found to
significantly decrease in aggressive HCC (24–26).
Unlike TACE, CCRT, a concurrent selective regional chemother-
apy with regional radiotherapy, has been shown to be an attractive,
FIGURE 3. Maximal-intensity-projection image (A) and transaxial
fused image (C) of 18F-FDG PET/CT and contrast-enhanced liver CT
(B) image of a 54-y-old man with HCC. On contrast-enhanced CT image
(B), infiltrative HCC is shown (arrow). HCC reveals mildly increased
18F-FDG uptake, with TLR of 1.6 (arrow). Patient was diagnosed at
BCLC stage C due to portal vein tumor thrombosis on CT images and
underwent CCRT. HCC progressed with intrahepatic metastases 15.6 mo
after CCRT, and patient died 19.8 mo after initial treatment.
FIGURE 2. Maximal-intensity-projection image (A) and transaxial
fused image (C) of 18F-FDG PET/CT and a contrast-enhanced liver CT
(B) image of a 65-y-old man with BCLC stage B HCC. Contrast-
enhanced CT image (B) shows enhanced HCC lesion with internal necrosis
in right lobe of liver (arrow). PET/CT image (C) shows intensely increased
18F-FDG uptake in mass, with TLR of 6.6 (arrow). Patient underwent
TACE, and cancer progressed with pulmonary metastases 2.0 mo after
TACE. Patient died 8.2 mo after initial treatment.
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alternative treatment modality that intensifies the effect of local
therapy while minimizing therapy-related complications (9,10).
In this study, patients treated with CCRT had larger tumors but
significantly better PFS and OS than those with TACE. Given that
the response to the initial treatment is a strong predictor for clinical
outcome (27), CCRT seems promising for intermediate-to-advanced
HCCs with increased 18F-FDG uptake. Recently, multimodality
treatment involving radiotherapy has been proven to be effective in
improving local tumor control in the setting of neoadjuvant, adjuvant,
and definitive treatment (9,28,29). In multimodality treatment, che-
motherapy can control micrometastasis as well as play the role of a
radiosensitizer (30). Because HCCs with aggressive features and
rapid tumor growth show high 18F-FDG uptake (15,31), the efficacy
of multimodality treatment might be more prominent in patients
with a high 18F-FDG uptake than that of monotherapy. This
hypothesis may explain why patients treated with CCRT, a mul-
timodality treatment, had better PFS and OS than those with
TACE as a monotherapy, particularly among patients with a
high18F-FDG uptake.
In the patient group with low 18F-FDG uptake, no significantly
different prognosis was noted between TACE and CCRT, implying
that the prognosis of well-differentiated or indolent HCCs might
be less affected by the treatment modality. However, in this study,
the 18F-FDG uptake of most patients was above the cutoff value
and only a small number of patients were included in the patient
group with low 18F-FDG uptake. Therefore, more studies with a
TABLE 2
Median Survival Time and Significance of Prognostic Factors for PFS
Variable
Univariate Multivariate
P Median (mo) P Hazard ratio (95% confidence interval)
Age (y) 0.002
#60 6.8





















Portal vein thrombosis 0.029
Absence 9.2
Presence 6.5 0.313





.2.0 6.2 0.009 1.55 (1.12–2.15)
HBV 5 hepatitis B virus; HCV 5 hepatitis C virus.
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TABLE 3
Median Survival Time and Significance of Prognostic Factors for OS
Variable
Univariate Multivariate with TLR
























Portal vein thrombosis 0.012
Absence 21.0
Presence 9.9 0.248





.2.0 9.1 ,0.001 1.97 (1.43–2.72)
HBV 5 hepatitis B virus; HCV 5 hepatitis C virus.
FIGURE 4. Cumulative PFS (A) and OS (B) curves according to
TLR of HCC.
FIGURE 5. Cumulative PFS (A) and OS (B) curves in patients treated
with TACE or CCRT.
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larger population are needed to compare the prognosis between
treatments in patients with a low 18F-FDG uptake.
There were several limitations in this study. First, because this
was a retrospective cohort study, the results were potentially
predisposed to selection bias due to the lack of randomization.
Further prospective, multicenter, randomized, registration studies
are needed to confirm the results of the present study. Second,
volumetric parameters such as metabolic tumor volume and total
lesion glycolysis rather than 18F-FDG uptake alone have acted as
better prognostic factors in various kinds of cancers (32,33);
however, there is no consensus on how to measure the volumetric
parameters of HCC (18). Therefore, only the TLR was measured
in the study. Last, PET/CT images were acquired from multiple
scanners at multiple medical centers. Regardless of the technical
feasibility of the standardization of scanners with a phantom, this
can often be impractical in routine clinical practice because of the
complexity of the procedures. Instead, use of the TLR can be a
beneficial, alternative PET/CT parameter that involves normaliz-
ing tumor values to the internal reference organ value.
CONCLUSION
In the present multicenter, retrospective, cohort study, 18F-FDG
uptake of HCCs was proven to be an independent prognostic factor
for PFS and OS in intermediate–to–advanced-stage HCC patients
without extrahepatic metastasis who underwent TACE or CCRT.
More important, only among patients with a high 18F-FDG uptake,
those treated with CCRT had a significantly better PFS and OS than
those treated with TACE. In contrast, there were no significant differ-
ences in PFS and OS between CCRT and TACE in patients with low
18F-FDG uptake. These results may support further prospective studies
evaluating the value of CCRT as an alternative initial treatment for
intermediate-to-advanced HCC patients with a high 18F-FDG uptake.
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